IL319748A - Pcsk9 inhibitors and methods of use thereof - Google Patents
Pcsk9 inhibitors and methods of use thereofInfo
- Publication number
- IL319748A IL319748A IL319748A IL31974825A IL319748A IL 319748 A IL319748 A IL 319748A IL 319748 A IL319748 A IL 319748A IL 31974825 A IL31974825 A IL 31974825A IL 319748 A IL319748 A IL 319748A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- pcsk9 inhibitors
- pcsk9
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263376791P | 2022-09-23 | 2022-09-23 | |
| US202363483797P | 2023-02-08 | 2023-02-08 | |
| US202363580500P | 2023-09-05 | 2023-09-05 | |
| PCT/EP2023/076197 WO2024062090A1 (en) | 2022-09-23 | 2023-09-22 | Pcsk9 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319748A true IL319748A (en) | 2025-05-01 |
Family
ID=88204310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319748A IL319748A (en) | 2022-09-23 | 2023-09-22 | Pcsk9 inhibitors and methods of use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240228469A1 (en) |
| EP (1) | EP4590397A1 (en) |
| JP (1) | JP2025532670A (en) |
| KR (1) | KR20250075662A (en) |
| CN (1) | CN120322430A (en) |
| AU (1) | AU2023345563A1 (en) |
| CA (1) | CA3268338A1 (en) |
| CL (1) | CL2025000822A1 (en) |
| CO (1) | CO2025004968A2 (en) |
| CR (1) | CR20250143A (en) |
| DO (1) | DOP2025000067A (en) |
| IL (1) | IL319748A (en) |
| MX (1) | MX2025003126A (en) |
| PE (1) | PE20251755A1 (en) |
| TW (1) | TW202430178A (en) |
| UY (1) | UY40445A (en) |
| WO (1) | WO2024062090A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4786462A1 (en) * | 2023-09-25 | 2026-08-05 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Pyridone compounds and preparation method therefor, and application |
| TW202539678A (en) * | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Pcsk9 inhibitors and methods of use thereof |
| TW202602886A (en) * | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Pcsk9 inhibitors and methods of use thereof |
| WO2025214500A1 (en) * | 2024-04-12 | 2025-10-16 | 上海翰森生物医药科技有限公司 | Free base crystal form of nitrogen-containing heterocyclic derivative, acid salt and crystal form thereof, preparation method therefor, and use thereof |
| TW202612699A (en) * | 2024-05-16 | 2026-04-01 | 瑞典商阿斯特捷利康公司 | Combination therapy |
| WO2026044073A1 (en) | 2024-08-22 | 2026-02-26 | Avioris Bio, Inc. | Pcsk9 inhibitors and methods of using the same |
| WO2026086805A1 (en) * | 2024-10-23 | 2026-04-30 | 深圳信立泰药业股份有限公司 | Pcsk9 and hmg-coa bicyclic compound, and preparation and use thereof |
| WO2026092600A1 (en) * | 2024-10-31 | 2026-05-07 | 石药集团中奇制药技术(石家庄)有限公司 | Nitrogen-containing heterocyclic compound and use thereof |
| WO2026109026A1 (en) * | 2024-11-25 | 2026-05-28 | 深圳信立泰药业股份有限公司 | Pcsk9 and lp(a) dual-target compound and use thereof |
| WO2026131688A2 (en) | 2024-12-16 | 2026-06-25 | Astrazeneca Ab | Crystalline forms and methods of synthesis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202134D0 (en) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (en) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | PCSK9 INHIBITORS AND METHODS OF USING THEM |
| WO2023084449A1 (en) * | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
-
2023
- 2023-09-20 US US18/470,548 patent/US20240228469A1/en active Pending
- 2023-09-22 CA CA3268338A patent/CA3268338A1/en active Pending
- 2023-09-22 JP JP2025517245A patent/JP2025532670A/en active Pending
- 2023-09-22 AU AU2023345563A patent/AU2023345563A1/en active Pending
- 2023-09-22 PE PE2025000643A patent/PE20251755A1/en unknown
- 2023-09-22 IL IL319748A patent/IL319748A/en unknown
- 2023-09-22 WO PCT/EP2023/076197 patent/WO2024062090A1/en not_active Ceased
- 2023-09-22 UY UY0001040445A patent/UY40445A/en unknown
- 2023-09-22 CR CR20250143A patent/CR20250143A/en unknown
- 2023-09-22 CN CN202380074481.8A patent/CN120322430A/en active Pending
- 2023-09-22 EP EP23777185.2A patent/EP4590397A1/en active Pending
- 2023-09-22 TW TW112136225A patent/TW202430178A/en unknown
- 2023-09-22 KR KR1020257013388A patent/KR20250075662A/en active Pending
-
2025
- 2025-03-18 MX MX2025003126A patent/MX2025003126A/en unknown
- 2025-03-20 DO DO2025000067A patent/DOP2025000067A/en unknown
- 2025-03-20 CL CL2025000822A patent/CL2025000822A1/en unknown
- 2025-04-22 CO CONC2025/0004968A patent/CO2025004968A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250075662A (en) | 2025-05-28 |
| MX2025003126A (en) | 2025-06-02 |
| UY40445A (en) | 2024-02-15 |
| EP4590397A1 (en) | 2025-07-30 |
| JP2025532670A (en) | 2025-10-01 |
| CL2025000822A1 (en) | 2025-06-23 |
| US20240228469A1 (en) | 2024-07-11 |
| DOP2025000067A (en) | 2025-06-30 |
| CA3268338A1 (en) | 2024-03-28 |
| CR20250143A (en) | 2025-06-10 |
| TW202430178A (en) | 2024-08-01 |
| AU2023345563A1 (en) | 2025-05-01 |
| CN120322430A (en) | 2025-07-15 |
| PE20251755A1 (en) | 2025-07-09 |
| WO2024062090A1 (en) | 2024-03-28 |
| CO2025004968A2 (en) | 2025-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297625B2 (en) | PI3K-alpha INHIBITORS AND METHODS OF USE THEREOF | |
| PT3911648T (en) | Pcsk9 inhibitors and methods of use thereof | |
| CA3268338A1 (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL327523A (en) | Ras inhibitors and methods of use thereof | |
| GB2595975B (en) | Inhibitors of cysteine proteases and methods of use thereof | |
| IL320388A (en) | Macrocyclic kras inhibitors and methods of use | |
| IL312348A (en) | Inhibitors of hif-2alpha and methods of use thereof | |
| IL284661A (en) | pcsk9 inhibitors and methods of using them | |
| IL318169A (en) | Inhibitors of apol1 and methods of using same | |
| IL316619A (en) | Pi3kα inhibitors and methods of use thereof | |
| IL321357A (en) | Inhibitors of kif18a and uses thereof | |
| IL314320A (en) | Compounds and methods of use | |
| EP4370124A4 (en) | PI3Ka INHIBITORS AND METHODS OF USE THEREOF | |
| IL299700A (en) | KCNT1 inhibitors and methods of use | |
| IL314330A (en) | APOL1 inhibitors and methods of use | |
| IL318393A (en) | Aza-quinazoline compounds and methods of use | |
| EP4329735A4 (en) | Kcnt1 inhibitors and methods of use | |
| SG11202101618PA (en) | Arginase inhibitors and methods of use thereof | |
| IL314277A (en) | Anti-b7-h3 compounds and methods of use | |
| LT4168409T (en) | Vmat2 inhibitors and methods of use | |
| IL321255A (en) | Adar1 inhibitors and methods of using the same | |
| IL327384A (en) | Cbl-b inhibitors and methods of uses thereof | |
| HK40127572A (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL320186A (en) | Ccr2 inhibitors and methods of use | |
| HK40108854A (en) | Kcnt1 inhibitors and methods of use |